Back to search

Article

Prognostic Risk Refinement using Artificial Intelligence in HR+/HER2- Early Breast Cancer: Implications for CDK4/6 Eligibility Criteria

2026-01-25

Abstract excerpt

Patient selection and enrolment into phase III randomized clinical trials (RCTs) of adjuvant cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapies depend on accurate risk definition. However, standard clinicopathologic criteria incompletely capture recurrence risk, limiting their efficacy in treatment selection. To assess whether artificial intelligence (AI)-enhanced prognostication may enrich the clinical...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1e55ee56-0108-54b6-971e-f5fe64323981
DOI
10.64898/2026.01.23.26344621
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Prognostic Risk Refinement using Artificial Intelligence in HR+/HER2- Early Breast Cancer: Implications for CDK4/6 Eligibility CriteriaDOI 10.64898/2026.01.23.26344621
Select a neighboring publication to make it the new centre.